Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002140510 | SCV002455115 | likely benign | not provided | 2025-01-14 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV002140510 | SCV005218766 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Fulgent Genetics, |
RCV005050541 | SCV005684350 | uncertain significance | Bone mineral density quantitative trait locus 1; Exudative vitreoretinopathy 4; Worth disease; Autosomal dominant osteopetrosis 1; Osteoporosis with pseudoglioma; Polycystic liver disease 4 with or without kidney cysts | 2024-04-25 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004744315 | SCV005363800 | uncertain significance | LRP5-related disorder | 2024-06-21 | no assertion criteria provided | clinical testing | The LRP5 c.1496A>G variant is predicted to result in the amino acid substitution p.Asn499Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.028% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |